Radionecrosis after repeated courses of radiotherapy under stereotactic conditions for brain metastases: Analysis of clinical and dosimetric data from a retrospective cohort of 184 patients.

Date publication

juin 2022

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine , Pr NOEL Georges , Dr CEBULA Hélène , Dr LE FEVRE Clara , Dr BUND Caroline

Tous les auteurs :
Kuntz L, Le Fèvre C, Jarnet D, Keller A, Meyer P, Cox DG, Bund C, Antoni D, Cebula H, Noel G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35715354

Résumé

Between 10 and 40% of patients with cancer will develop one or more brain metastases (BMs). Stereotactic radiotherapy (SRT) is part of the therapeutic arsenal for the treatment of de novo or recurrent BM. Its main interest is to delay whole brain radiation therapy (WBRT), which may cause cognitive toxicity. However, SRT is not exempt from long-term toxicity, and the most widely known SRT is radionecrosis (RN). The objective of this study was to analyze the occurrence of RN per BM and per patient.

Mots clés

Brain metastases, Métastases cérébrales, Radionecrosis, Radionécrose, Repeated radiosurgery, Réirradiation, Salvage radiation, Stereotactic radiosurgery, Stéréotaxie, Toxicity, Toxicité, Traitement de rattrapage

Référence

Cancer Radiother. 2022 06 14;: